GlaxoSmithKline

View All

Business CockTail

GlaxoSmithKline taps Baltimore’s Insilico for AI-based drug discovery GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter’s artificial intelligence technology can aid in the drug discovery process. The duo kept mum on the details but said the agreement comes after Baltimore-based Insilico ...

Find More

Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO

Stada’s €5.3B buyout Sinks, brings in new CEO and CFO After failing to win the shareholder support needed to complete a €5.32 billion buyout, Stada is changing key executives. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helmut Kraft following a board meeting on Tuesday and quickly appoi...

Find More

AKT Inhibitors: A potential Cancer Immunotherapy Target

Targeted therapy is the most preferred option for cancer treatment and a number of new targets are being discovered which target cancer specific receptors, AKT being one of them. Protein kinase B (PKB), also known as AKT, belongs to serine/threonine protein kinase superfamily. AKT has been validated as a potential t...

Find More

AstraZeneca’s new Asthma Drug Aces Phase III trial

AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year. The drug, Benralizumab, is a new biological treatment for people with severe asthma, and works by targeting eosinophils that cause inflammation in the lungs of ...

Find More